Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

Farrokh Dehdashti; Ningying Wu; Cynthia X. Ma; Michael J. Naughton; John A. Katzenellenbogen; Barry A. Siegel

doi:10.1038/s41467-020-20814-9

Nature Communications (Feb 2021)

Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

Farrokh Dehdashti,
Ningying Wu,
Cynthia X. Ma,
Michael J. Naughton,
John A. Katzenellenbogen,
Barry A. Siegel

Affiliations

Farrokh Dehdashti: Alvin J. Siteman Cancer Center, Washington University School of Medicine
Ningying Wu: Alvin J. Siteman Cancer Center, Washington University School of Medicine
Cynthia X. Ma: Alvin J. Siteman Cancer Center, Washington University School of Medicine
Michael J. Naughton: Saint Francis Healthcare, Cape Medical Oncology
John A. Katzenellenbogen: Department of Chemistry and Cancer Center, University of Illinois
Barry A. Siegel: Alvin J. Siteman Cancer Center, Washington University School of Medicine

DOI: https://doi.org/10.1038/s41467-020-20814-9
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 9

Abstract

Read online

Clinical estrogen receptor (ER) testing for breast cancer is limited in predicting response to endocrine therapy (ET). In this phase 2 clinical trial, authors demonstrate that the responsiveness to ET can be predicted by use of PET/CT with 21-[18F]fluorofuranylnorprogesterone (FFNP) to detect the change in tumor progesterone receptor (PgR) levels after a one-day estradiol challenge.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal